Jazz Pharmaceuticals Company Insiders
| JAZZ Stock | USD 125.05 0.42 0.34% |
Jazz Pharmaceuticals employs about 2.8 K people. The company is managed by 15 executives with a total tenure of roughly 23 years, averaging almost 1.0 years of service per executive, having 186.67 employees per reported executive. Break down of Jazz Pharmaceuticals' management performance can provide insight into the company performance.
| Bruce Cozadd Chairman Co-Founder, Executive Chairman and CEO |
Jazz |
Jazz Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.0462 % which means that it generated a profit of $0.0462 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1209 %, meaning that it created $0.1209 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Jazz Pharmaceuticals Workforce Comparison
Jazz Pharmaceuticals PLC is rated fourth overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 28,363. Jazz Pharmaceuticals holds roughly 2,800 in number of employees claiming about 10% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.25 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.25. Jazz Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jazz Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jazz Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Jazz Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bruce Cozadd over a month ago Disposition of 1500 shares by Bruce Cozadd of Jazz Pharmaceuticals at 123.43 subject to Rule 16b-3 | ||
Bruce Cozadd over three months ago Disposition of 1000 shares by Bruce Cozadd of Jazz Pharmaceuticals at 110.84 subject to Rule 16b-3 | ||
Patricia Carr over six months ago Disposition of 163 shares by Patricia Carr of Jazz Pharmaceuticals at 108.825 subject to Rule 16b-3 | ||
Kennedy Patrick over six months ago Insider Trading | ||
Rick Winningham over a year ago Acquisition by Rick Winningham of 3075 shares of Jazz Pharmaceuticals subject to Rule 16b-3 | ||
Matthew Young over a year ago Payment of 1348 shares by Matthew Young of Jazz Pharmaceuticals subject to Rule 16b-3 |
Jazz Pharmaceuticals Notable Stakeholders
A Jazz Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Jazz Pharmaceuticals often face trade-offs trying to please all of them. Jazz Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Jazz Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Bruce Cozadd | Co-Founder, Executive Chairman and CEO | Profile | |
| Renee Gala | President COO | Profile | |
| Rene Gal | President COO | Profile | |
| Philip Johnson | Executive CFO | Profile | |
| Finbar Larkin | VP Operations | Profile | |
| George Eliades | Senior Officer | Profile | |
| Daniel Swisher | NonExecutive Employee | Profile | |
| Patricia Carr | Senior Officer | Profile | |
| Jed MD | Senior Medicine | Profile | |
| Andrea Flynn | VP Relations | Profile | |
| Robert MD | Executive Development | Profile | |
| John Miller | Senior Strategy | Profile | |
| Heidi Manna | Executive Officer | Profile | |
| Neena JD | Executive Officer | Profile | |
| Samantha Pearce | Senior International | Profile |
About Jazz Pharmaceuticals Management Performance
The success or failure of an entity such as Jazz Pharmaceuticals PLC often depends on how effective the management is. Jazz Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Jazz management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Jazz management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland. Jazz Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3200 people.
Please note, the imprecision that can be found in Jazz Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Jazz Pharmaceuticals PLC. Check Jazz Pharmaceuticals' Beneish M Score to see the likelihood of Jazz Pharmaceuticals' management manipulating its earnings.
Jazz Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Jazz Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Jazz Pharmaceuticals within its industry.Jazz Pharmaceuticals Manpower Efficiency
Return on Jazz Pharmaceuticals Manpower
| Revenue Per Employee | 1.4M | |
| Revenue Per Executive | 255.6M | |
| Net Income Per Employee | 148.2K | |
| Net Income Per Executive | 27.7M | |
| Working Capital Per Employee | 678.1K | |
| Working Capital Per Executive | 126.6M |
Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.